Amy Bullock

1.2k total citations · 1 hit paper
22 papers, 949 citations indexed

About

Amy Bullock is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Biological Psychiatry. According to data from OpenAlex, Amy Bullock has authored 22 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Cellular and Molecular Neuroscience and 5 papers in Biological Psychiatry. Recurrent topics in Amy Bullock's work include Nicotinic Acetylcholine Receptors Study (8 papers), Neuroscience and Neuropharmacology Research (7 papers) and Receptor Mechanisms and Signaling (7 papers). Amy Bullock is often cited by papers focused on Nicotinic Acetylcholine Receptors Study (8 papers), Neuroscience and Neuropharmacology Research (7 papers) and Receptor Mechanisms and Signaling (7 papers). Amy Bullock collaborates with scholars based in United States. Amy Bullock's co-authors include Allan C. Collins, Michael J. Marks, A C Collins, Sharon R. Grady, Jerry A. Stitzel, Jean‐Pierre Changeux, Marina R. Picciotto, Paul Whiteaker, James Doherty and Amy L. Clark and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Brain Research.

In The Last Decade

Amy Bullock

22 papers receiving 923 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zuranolone for the Treatment of Postpartum Depression

2023 93 citations Kristina M. Deligiannidis, Samantha Meltzer‐Brody et al. American Journal of Psychiatry profile →

Peers

Countries citing papers authored by Amy Bullock

Since Specialization

Citations

This map shows the geographic impact of Amy Bullock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Bullock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Bullock more than expected).

Fields of papers citing papers by Amy Bullock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Bullock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Bullock. The network helps show where Amy Bullock may publish in the future.

Co-authorship network of co-authors of Amy Bullock

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Bullock. A scholar is included among the top collaborators of Amy Bullock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Bullock. Amy Bullock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of zuranolone on insomnia symptoms in patients with postpartum depression in the SKYLARK study 2023 ·American Journal of Obstetrics and Gynecology ·(unknown), Kristina M. Deligiannidis, Samantha Meltzer‐Brody, (unknown), Robert Lasser, Amy Bullock, (unknown), (unknown), Fiona Forrestal, (unknown), (unknown), Jim Doherty	3
2	Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study 2023 ·Neuropsychopharmacology ·Sagar V. Parikh, Scott T. Aaronson, Sanjay J. Mathew, Gustavo Alva, Charles DeBattista, Stephen Kanes, Robert Lasser, Amy Bullock, (unknown), JungAh Jung, Fiona Forrestal, (unknown), (unknown), (unknown), James Doherty	15
3	Zuranolone for the Treatment of Postpartum Depression breakdown → 2023 ·American Journal of Psychiatry ·Kristina M. Deligiannidis, Samantha Meltzer‐Brody, (unknown), (unknown), Marlene P. Freeman, Robert Lasser, Amy Bullock, (unknown), Sigui Li, Fiona Forrestal, (unknown), (unknown), (unknown), James Doherty	93
4	Improvement in HAMD-17 Subscale Scores With 14-Day Treatment Course of Zuranolone in Postpartum Depression: Results From the SKYLARK Study [ID: 1372313] 2023 ·Obstetrics and Gynecology ·Kristina M. Deligiannidis, Amy Bullock, (unknown), Sigui Li, (unknown), (unknown)	1
5	A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults 2021 ·Human Psychopharmacology Clinical and Experimental ·Amy Bullock, Handan Gunduz‐Bruce, Gary Zammit, (unknown), Haihong Li, Abdul J. Sankoh, Christopher Silber, Stephen Kanes, Jeffrey M. Jonas, James Doherty	15
6	Mechanistic PK/PD Model of Neuroactive Steroid GABAA Positive Allosteric Modulation and Effects on TETRAS Assessment in Essential Tremor (4499) 2020 ·Neurology ·David P. Nguyen, Anne C. Smith, (unknown), E. Hoffman, James Paskavitz, Angela Wehr, (unknown), Amy Bullock, Abdul J. Sankoh, Albert J. Robichaud, Stephen Kanes, James Doherty, Michael C. Quirk	1
7	Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study 2020 ·Journal of the Neurological Sciences ·Amy Bullock, Inder Kaul, Sigui Li, Christopher Silber, James Doherty, Stephen Kanes	19
8	SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies 2019 ·Clinical Pharmacokinetics ·Ethan Hoffmann, George G. Nomikos, Inder Kaul, Shane Raines, (unknown), Amy Bullock, Abdul J. Sankoh, James Doherty, Stephen Kanes, Helen Colquhoun	45
9	Chronic corticosterone treatment alters sensory gating in C3H mice 2001 ·Pharmacology Biochemistry and Behavior ·Karen E. Stevens, Amy Bullock, Allan C. Collins	35
10	Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit. 1999 ·PubMed ·Michael J. Marks, Paul Whiteaker, (unknown), Jerry A. Stitzel, Amy Bullock, S. R. Grady, Marina R. Picciotto, Jean‐Pierre Changeux, A C Collins	116
11	Two Pharmacologically Distinct Components of Nicotinic Receptor-Mediated Rubidium Efflux in Mouse Brain Require the β2 Subunit 1999 ·Journal of Pharmacology and Experimental Therapeutics ·Michael J. Marks, Paul Whiteaker, (unknown), Jerry A. Stitzel, Amy Bullock, Sharon R. Grady, Marina R. Picciotto, Jean‐Pierre Changeux, A C Collins	75
12	Neurosteroids Modulate Nicotinic Receptor Function in Mouse Striatal and Thalamic Synaptosomes 1997 ·Journal of Neurochemistry ·Amy Bullock, Amy L. Clark, Sharon R. Grady, Scott Robinson, (unknown), Michael J. Marks, Allan C. Collins	105
13	Inbred mouse strains differ in the regulation of startle and prepulse inhibition of the startle response. 1997 ·Behavioral Neuroscience ·Amy Bullock, (unknown), (unknown), Allan C. Collins	102
14	Long‐Term Ethanol and Nicotine Treatment Elicit Tolerance to Ethanol 1996 ·Alcoholism Clinical and Experimental Research ·Allan C. Collins, Lincoln H. Wilkins, (unknown), (unknown), Amy Bullock	59
15	Corticosterone reversibly alters brain α-bungarotoxin binding and nicotine sensitivity 1995 ·Pharmacology Biochemistry and Behavior ·(unknown), James R. Pauly, Amy Bullock, Allan C. Collins	15
16	Sodium channel blockers partially inhibit nicotine-stimulated 86Rb+ efflux from mouse brain synaptosomes. 1995 ·Journal of Pharmacology and Experimental Therapeutics ·Michael J. Marks, Amy Bullock, A C Collins	29
17	Nicotine Tolerance in Chromaffin Cell Cultures: Acute and Chronic Exposure to Smoking‐Related Nicotine Doses 1994 ·Journal of Neurochemistry ·Amy Bullock, (unknown), Allan S. Schneider	13
18	μ Opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain 1989 ·European Journal of Pharmacology ·Milt Titeler, Robert A. Lyon, Michael J. Kuhar, (unknown), Robert F. Dannals, Sigrun Leonhardt, Amy Bullock, (unknown), Donald L. Price, Robert G. Struble	64
19	2-(Alkylamino)tetralin derivatives: interaction with 5-HT1A serotonin binding sites 1989 ·Journal of Medicinal Chemistry ·Noreen Naiman, Robert A. Lyon, Amy Bullock, (unknown), Milt Titeler, Richard A. Glennon	18
20	Basal and amphetamine-induced asymmetries in striatal dopamine release and metabolism: bilateral in vivo microdialysis in normal rats 1988 ·Brain Research ·S.D. Glick, Jeffrey Carlson, (unknown), I.M. Maisonneuve, Amy Bullock	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact